TransGenic Group

TransGenic Group Market Cap per Employee

The Market Cap per Employee of TransGenic Group (2342.T) as of Nov 11, 2026 is 21.58 M JPY. In the previous year, Market Cap per Employee was 21.58 M JPY — a change of 0.00% (lower).

Market Cap per Employee

21.58 MJPY

YoY

0.00%

Last updated:

Market Cap per Employee of TransGenic Group is 2026 21.58 M JPY. Market Cap per Employee of TransGenic Group was 2025 21.58 M JPY. It decreases by 0.00% lower compared to the previous year.

The TransGenic Group Market Cap per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Cap per Employee
Date
Market Cap per Employee
Jan 1, 2019
21.58 M JPY
Jan 1, 2020
21.58 M JPY
Jan 1, 2021
21.58 M JPY
Jan 1, 2022
21.58 M JPY
Jan 1, 2023
21.58 M JPY
Jan 1, 2024
21.58 M JPY
Jan 1, 2025
21.58 M JPY
Jan 1, 2026
21.58 M JPY
The TransGenic Group Market Cap per Employee history
YEARMarket Cap per EmployeeYoY
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY0.00%
21.58 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Market Cap per Employee of TransGenic Group is 21.58 M JPY in 2026.

Market Cap per Employee of TransGenic Group changed from 21.58 M JPY to 21.58 M JPY, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Market Cap per Employee TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

Market cap per employee shows the market value attributed to each employee. Technology companies typically have higher values due to intellectual capital.

Market Cap per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Market Cap per Employee's TransGenic Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — TransGenic Group

All Key Metrics — TransGenic Group